Comparison of Pulmonary Deposition for Single and Multidose Dry Powder Inhalers with Indacaterol and Glycopyrrolate

An inhaled combination of indacaterol maleate and glycopyrronium bromide is routinely prescribed for the management of chronic obstructive pulmonary disease.

This paper describes work to determine the suitability of using a multi-unit dose dry powder inhaler to deliver this formulation in place of the single unit dose device associated with current commercial products. The results of in vitro and in silico studies indicate no difference in aerodynamic distribution or regional deposition respectively, between the two devices. This suggests comparable pulmonary performance and potential for interchangeability. The multi-unit dry powder inhaler offers practical advantages, such as eliminating the need to handle capsules, and requires a reduced inspiratory flow for effective drug delivery, making it the more patient-friendly option.